Abstracts tagged "Sjogren’s syndrome and outcome measures"

Abstract Number: 2551 • 2012 ACR/ARHP Annual Meeting
Validation of EULAR Primary Sjögren’s Syndrome Disease Activity and Patient Indexes
Raphaèle Seror¹, Elke Theander², Johan G. Brun³, Manel Ramos-Casals⁴, Valeria Valim⁵, Thomas Dorner⁶, Xavier Mariette⁷, Hendrika Bootsma⁸, Athanasios G. Tzioufas⁹, Roser Solans-Laqué¹⁰, Jacques-Eric Gottenberg¹¹, Eric Hachulla¹², Wan-Fai NG¹³, Stefano Bombardieri¹⁴, Roberto Gerli¹⁵, Takayuki Sumida¹⁶, Alain Saraux¹⁷, Matija Tomsic¹⁸, Roberto Caporali¹⁹, Roberta Priori²⁰, Kathy Moser Sivils²¹, A.a. Kruize²², Cristina F. Vollenweider²³, Claudio Vitali²⁴ and Simon J. Bowman²⁵, ¹Rheumatology, Bicetre university hospital, LE Kremlin-Bicetre, France, ²Dept of Rheumatology, Skane University Hospital, Lund University, Malmö, Sweden, ³Department of Rheumatology, Haukeland University Hospital, Bergen, Norway, ⁴Laboratorio de Enfermedades Autoinmunes Josep Font, Hospital Clínic, Barcelona, Spain, ⁵Clínica Médica - Reumatologia, Universidade Federal do Espírito Santo, Vitória, Brazil, ⁶Department of Medicine/Rheumatology and Clinical Immunology and German Rheumatism Research Centre Berlin (DRFZ), Charité University Medicine Berlin, Berlin, Germany, ⁷Rheumatology, Université Paris-Sud, Le Kremlin Bicetre, France, ⁸Department of Rheumatology and Clinical Immunology, University Medical Center Groningen, Groningen, Netherlands, ⁹Pathophysiology, School of Medicine, National University of Athens, Athens, Greece, ¹⁰Internal Medicine, Senior Consultant, Barcelona, Spain, ¹¹Rheumatology, Strasbourg University Hospital, Strasbourg, France, ¹²Department of Internal Medicine, Claude Huriez University Hospital, Lille, France, ¹³Departement of rheumatology, New-Castle University Hospital,, Departement of rheumatology, New-Castle University Hospital, UK, Newcastle, England, ¹⁴Department of Clinical and Experimental Medicine, Rheumatology Unit, University of Pisa, Pisa, Italy, ¹⁵Rheumatology Unit, University of Perugia, Perugia, Italy, ¹⁶Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba City, Japan, ¹⁷Department of rheumatology and unit of immunology (EA 2216), Université Brest Occidentale, Brest, France, ¹⁸Department of Rheumatology, University Medical Centre Ljubjana, Ljubljana, Slovenia, ¹⁹Division of Rheumatology, IRCCSPoliclinico S. Matteo Foundation, Pavia, Italy, ²⁰Department of Internal Medicine and Medical Specialties, Sapienza University, Rome, Italy, ²¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²²Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ²³Rheumatology, German Hospital, Buenos Aires, Argentina, ²⁴Casa di Cura di Lecco, Lecco, Italy, ²⁵Department of Rheumatology, Queen Elizabeth Hospital Birmingham, Birmingham, United Kingdom
Background/Purpose: To validate the EULAR scores for assessment of primary Sjögren's Syndrome (SS): the EULAR SS Disease Activity Index (ESSDAI), the EULAR SS Patient Reported…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].